PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 12, 2024Clinical Infectious Diseases17 citationsOpen Access

Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV

View Full Paper
JDJosé DamasAMAline MuntingJFJacques Fellay

Key Points

Key points are not available for this paper at this time.

Abstract

Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Damas et al. (2024) studied this question.

synapsesocial.com/papers/68e6f5edb6db64358766ff9fhttps://doi.org/10.1093/cid/ciae189
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG2022 · 57 citations
  2. 2Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men2010 · 5,170 citations
  3. 3Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study2014 · 80 citations
  4. 4Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study2016 · 29 citations
  5. 5Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study2011 · 620 citations